SMARCA2 and central nervous system cancer: To systematically characterize protein and phosphorylation alterations in brain tumors and distinguish BrM from glioma in a pathological feature‐ and disease‐specific manner, we performed separate and integrative analyses of the two types of brain tumors with paired NATs.